Stockreport

Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease

Aldeyra Therapeutics, Inc.  (ALDX) 
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aldeyra.com/investor-relations
PDF Primary objective of RENEW Part 1 achieved: Induction-maintenance dosing regimen of topical ocular reproxalap advanced to RENEW Part 2Reproxalap statistically superior t [Read more]